Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.

Journal of medicinal chemistry - 12 Jun 2014

Kolocouris Antonios, Tzitzoglaki Christina, Johnson F Brent, Zell Roland, Wright Anna K, Cross Timothy A, Tietjen Ian, Fedida David, Busath David D

Abstract excerpt

A series of 2-adamantanamines with alkyl adducts of various lengths were examined for efficacy against strains of influenza A including those having an S31N mutation in M2 proton channel that confer resistance to amantadine and rimantadine. The addition of as little as one CH2 group to the methyl adduct of the amantadine/rimantadine analogue, 2-methyl-2-aminoadamantane, led to activity in vitro against two M2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amantadine
Share to Dogs

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Multiple, Viral

Share to HEK293 Cells

Share to Influenza A Virus, H1N1 Subtype

Share to Ion Channels

Share to Madin Darby Canine Kidney Cells

Share to Viral Matrix Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 24793875
DOI: 10.1021/jm500598u
PMCID: PMC4127532

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aminoadamantanes with persistent in vitro efficacy against H1N1 (2009) influenza A.PMID 24793875Read ↗

Antiviral mechanisms and preclinical evaluation of amantadine analogs that continue to inhibit influenza A viruses with M2S31N-based drug resistance.Semantic proximity Read ↗

A Study of the Activity of Adamantyl Amines against Mutant Influenza A M2 Channels Identified a Polycyclic Cage Amine Triple Blocker, Explored by Molecular Dynamics Simulations and Solid-State NMR.Semantic proximity Read ↗

Discovery of novel dual inhibitors of the wild-type and the most prevalent drug-resistant mutant, S31N, of the M2 proton channel from influenza A virus.Semantic proximity Read ↗

Chemical Probes for Blocking of Influenza A M2 Wild-type and S31N Channels.Semantic proximity Read ↗

An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.Semantic proximity Read ↗

Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus.Semantic proximity Read ↗

Easily accessible polycyclic amines that inhibit the wild-type and amantadine-resistant mutants of the M2 channel of influenza A virus.Semantic proximity Read ↗

How do aminoadamantanes block the influenza M2 channel, and how does resistance develop?Semantic proximity Read ↗

Discovery of M2 channel blockers targeting the drug-resistant double mutants M2-S31N/L26I and M2-S31N/V27A from the influenza A viruses.Semantic proximity Read ↗

Slow but Steady Wins the Race: Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus.Semantic proximity Read ↗

Drug-induced conformational and dynamical changes of the S31N mutant of the influenza M2 proton channel investigated by solid-state NMR.Semantic proximity Read ↗

Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with in vivo antiviral efficacy against both oseltamivir sensitive and -resistant influenza A viruses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.